Allogene Therapeutics Files 8-K on Shareholder Vote & Exhibits
Ticker: ALLO · Form: 8-K · Filed: Jun 23, 2025 · CIK: 1737287
| Field | Detail |
|---|---|
| Company | Allogene Therapeutics, Inc. (ALLO) |
| Form Type | 8-K |
| Filed Date | Jun 23, 2025 |
| Risk Level | low |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, filing
Related Tickers: ALLO
TL;DR
ALLO filed an 8-K for shareholder votes and financials - details to come.
AI Summary
On June 18, 2025, Allogene Therapeutics, Inc. filed an 8-K report detailing a submission of matters to a vote of security holders and financial statements and exhibits. The filing does not contain specific financial figures or details about the matters to be voted upon.
Why It Matters
This filing indicates upcoming shareholder decisions and the release of financial information, which could impact investor sentiment and the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is procedural and does not disclose new material financial information or significant corporate events that would immediately impact risk.
Key Players & Entities
- Allogene Therapeutics, Inc. (company) — Registrant
- June 18, 2025 (date) — Earliest event reported
- 210 East Grand Avenue, South San Francisco, California 94080 (address) — Principal executive offices
FAQ
What specific matters will be submitted to a vote of Allogene Therapeutics' security holders?
The filing indicates that matters will be submitted to a vote, but the specific details of these matters are not provided in this 8-K report.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on June 18, 2025.
What is the primary business of Allogene Therapeutics, Inc. according to the filing?
Allogene Therapeutics, Inc. is involved in Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].
Where are Allogene Therapeutics' principal executive offices located?
Allogene Therapeutics' principal executive offices are located at 210 East Grand Avenue, South San Francisco, California 94080.
What is the SEC file number for Allogene Therapeutics, Inc.?
The SEC file number for Allogene Therapeutics, Inc. is 001-38693.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 23, 2025 regarding Allogene Therapeutics, Inc. (ALLO).